Antiviral therapy for chronic hepatitis B must be discontinued according to guideline criteria. For HBeAg-positive patients, consolidate therapy for one year after initial treatment to achieve HBeAg serologic conversion; for HBeAg-negative patients, the total course of therapy should be at least 2.5 years; consolidate therapy for 1.5 years after treatment to achieve sustained virologic control, and extend therapy if necessary to reduce relapses. After the end of treatment, regular follow-up, with signs of relapse and evidence of disease progression, start antiviral treatment again. In particular, it has been demonstrated that in HBeAg-negative hepatitis B patients, the only way to effectively reduce the high relapse rate after drug discontinuation is to achieve HBsAg serologic conversion.